Myelofibrosis: Part II –A focus on the management of the disease in Malaysia

Myelofibrosis: Part II –A focus on the management of the disease in Malaysia

OncologyGeneral PracticeHaematology
A badge with ribbon in color black 1 point | An analog clock in color black 32 minutes | A black calendar with white triangle in center that has a black exclamation point in the middle 01 Oct 2022 

Overview

Making clinical decisions in the management of myelofibrosis (MF) can be challenging owing to the heterogeneity of the disease, patient population and their often burdensome clinical manifestations. The goal of this learning activity is to provide doctors with a concise review of the management of MF.


Upon completing this module, participants will have a better understanding of the following aspects:

- Current treatment guidelines

- Role of available pharmacotherapy and nonpharmacotherapy

- Switching between treatments

- Challenges in treatment


CPD reviewer:

Dr Haifa Kathrin Al-Ali, MD, PD

Associate Professor

Department of Haematology and Medical Oncology

University Hospital of Halle (Saale)

Germany


• Lecture

• Q&A session


Who should participate:

• Doctors


NOTE :

Please watch the video before attempting the assessment questions.


Terms & Conditions:

Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point.

MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points


To play this video, you are required to have a media player such as Windows Media Player (PC), QuickTime (MAC) or another third party media player.


Sponsored by:

Novartis_logo.jpg